- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03603327
Response Guided Treatment With Direct Acting Anti-Viral Medications for Chronic HCV Infection
February 17, 2021 updated by: Ohad Etzion, Soroka University Medical Center
Efficacy and Safety of Response Guided Treatment With Direct Acting Anti-Viral Medications for Chronic HCV Infection - A Pilot Study
To evaluate the efficacy and safety of direct acting anti-viral agents (DAA) therapy in chronically infected Hepatitis C Virus (HCV) patients using an individualized response guided therapy (RGT) model.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Treatment of HCV infection is directed at achieving sustained virological response (SVR), defined as the continued absence of detectable HCV RNA for 12 or more weeks after completion of therapy Given the limited resources available for the costly DAA treatment, implementation of a response-guided treatment (RGT) model to individualize length of DAA therapy in a prospective setting could result in substantial cost saving on HCV drug expenditure in addition to improving patients' compliance to treatment.
Furthermore, if adopted at a larger scale, incorporation of such model into clinical practice may enable expansion of access to DAA therapy for patients who are currently not included in the various treatment programs, especially in resource-limited countries.
Study Type
Interventional
Enrollment (Actual)
30
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Be'er Sheva, Israel
- Soroka UMC
-
Petah Tikva, Israel
- Rabin Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Signed informed consent
- Clalit insured patients
- Female and male over the age of 18
- Capacity to provide written informed consent
- HCV RNA Viral Load (VL) larger than 105 IU/mL at screening and on at least one other occasion 6 months or more prior to the most recent HCV RNA test result.
- HCV genotypes 1a, 1b, 2, 3 or 4
Liver fibrosis stage 0-4 as determined by one of the following methods performed within 2 years prior to the screening visit:
- Fibrotest
- Transient elastography
- Liver biopsy using the METAVIR scoring system.
Patients must have the following laboratory parameters within 3 months of screening
- ALT and AST ≤ x10 the upper limit of normal (ULN)
- Direct bilirubin ≤ 1.5 the ULN
- Platelet count ≥70,000
- Hemoglobin ≥10 mg/dL
- Albumin ≥3 mg/dL
- INR ≤ 1.5 x ULN
- eGFR ≥ 60 mL/min as calculated by the Cockroft-Gault equation.
- Abdominal ultrasound, C.T or MRI scan showing no evidence of a focal lesion suspicious of hepatocellular carcinoma within 6 months of enrollment.
A female patient will be eligible to enter the study if it is confirmed that she is:
- Not pregnant or nursing
- Of non-childbearing potential (following hysterectomy, bilateral oophorectomy or post-menopausal)
- Women of childbearing potential- must have a negative urine pregnancy test at baseline and willing to use an accepted mechanical, medical or surgical birth control method from the day of screening until 90 days from the last dose of study drug.
- All male participants in the study must agree to consistently and correctly use a condom, while their female partner agrees to use one of the above-mentioned birth control methods from the day of screening until 90 days after the last dose of study drug.
- Patient must be able to comply with the dosing instructions for the study drug administration and able to complete the study schedule of assessments including all required post-treatment visits.
Exclusion Criteria:
- Clinical, serologic or histopathological evidence supporting the presence of chronic liver disease other than HCV (Including but not limited to: HBV, HDV or HIV coinfection, non-alcoholic steatohepatitis, alcoholic liver disease, Wilson's disease, A1AT deficiency and Celiac disease). Workup performed within 6 months of recruitment will be considered sufficient to exclude the above-mentioned conditions (except for A1AT deficiency and Wilson's disease for which exclusion at any time point qualifies).
Current or past history of any of the following:
- Clinically significant illness (other than HCV) or any other medical disorder that may interfere with patient's assessment, treatment or compliance with the protocol. Examples include congestive heart disease with moderate to severe left ventricular function and chronic obstructive pulmonary disease requiring chronic corticosteroid therapy.
- Clinical evidence of decompensated liver disease (e.g. ascites, bleeding esophageal varices, spontaneous bacterial peritonitis, encephalopathy or hepatorenal syndrome.)
- Child Pugh score higher than 6
- Gastrointestinal disorder or post-operative condition that may interfere with the absorption of the study drug.
- Solid organ transplantation
- Malignancy within 5 years prior to screening with the exception of specific cancers that are entirely cured by surgical resection (basal cell skin cancer etc.) Patients under the evaluation for possible malignancy are not eligible.
- Any prior treatment with a DAA (protease inhibitors, NS5A inhibitors, NS5B polymerase inhibitors/non-nucleoside polymerase inhibitors)
- Use of anti-viral medications within 30 days of screening.
- Chronic use of systemically administered immunosuppressive/immune- modulating medications
- Clinically relevant substance abuse within 6 months of enrollment. Patient with prior history of drug addiction who are currently maintained on a stable dose of opiate substitutes (naloxone) will be allowed to participate in the study if they can provide documentation of repeated negative toxicology screens from the 6 months prior to screening.
- Participating in clinical trial 30 days before screening.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Treatment
All subjects will receive a standard of care treatment- Direct acting anti-viral agents Drugs
|
Standard of care for Hepatitis C treatment
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of sustained virological response (SVR)
Time Frame: at 12 weeks after the end of treatment in all patients who received at least 4 weeks of therapy with any of the 5 optional drug regimens.
|
Sustained virological response (SVR), defined as an HCV RNA level of less than 10 IU/mL and measured by the Cepheid GeneXpert essay.
|
at 12 weeks after the end of treatment in all patients who received at least 4 weeks of therapy with any of the 5 optional drug regimens.
|
The percentage of patients in whom duration of treatment with DAA can be shortened to less than 12 weeks.
Time Frame: through study completion, an average of 1 year
|
through study completion, an average of 1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Ohad Etzion, MD, Soroka UMC
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 25, 2018
Primary Completion (Actual)
December 31, 2020
Study Completion (Actual)
December 31, 2020
Study Registration Dates
First Submitted
June 13, 2018
First Submitted That Met QC Criteria
July 26, 2018
First Posted (Actual)
July 27, 2018
Study Record Updates
Last Update Posted (Actual)
February 18, 2021
Last Update Submitted That Met QC Criteria
February 17, 2021
Last Verified
February 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0285-17-SOR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatitis C
-
Tripep ABInovio PharmaceuticalsUnknownChronic Hepatitis C Virus InfectionSweden
-
Hadassah Medical OrganizationXTL BiopharmaceuticalsWithdrawnChronic Hepatitis C Virus InfectionIsrael
-
Hadassah Medical OrganizationUnknownChronic Hepatitis C Virus InfectionIsrael
-
AbbVieCompletedHepatitis C Virus | Chronic Hepatitis C Virus
-
AbbVie (prior sponsor, Abbott)CompletedHepatitis C | Chronic Hepatitis C Infection | HCV | Hepatitis C Genotype 1United States
-
AbbVieCompletedChronic Hepatitis C | Hepatitis C (HCV) | Hepatitis C Genotype 1a
-
AbbVie (prior sponsor, Abbott)CompletedChronic Hepatitis C | Hepatitis C Genotype 1 | Hepatitis C (HCV)United States, Australia, Canada, France, Germany, New Zealand, Puerto Rico, Spain, United Kingdom
-
Trek Therapeutics, PBCCompletedChronic Hepatitis C | Hepatitis C Genotype 1 | Hepatitis C (HCV) | Hepatitis C Viral InfectionUnited States, New Zealand
-
Trek Therapeutics, PBCCompletedChronic Hepatitis C | Hepatitis C (HCV) | Hepatitis C Genotype 4 | Hepatitis C Viral InfectionUnited States
-
Beni-Suef UniversityCompletedChronic Hepatitis C Virus InfectionEgypt
Clinical Trials on Direct acting anti-viral agents
-
Massachusetts General HospitalWithdrawnHepatitis C | Kidney Failure
-
Postgraduate Institute of Medical Education and...UnknownHepatitis C | Public Health | Direct Acting Antiviral Agents | Resistance Associated SubstitutionsIndia
-
The Task Force for Global HealthCenters for Disease Control and PreventionRecruitingHepatitis CUnited States
-
University of Maryland, BaltimoreWithdrawn
-
Kaiser PermanentePatient-Centered Outcomes Research Institute; OneFlorida Clinical Research...Completed
-
Hospices Civils de LyonCompleted
-
Assiut UniversityUnknown
-
Virginia Commonwealth UniversityCompletedHepatitis C | Kidney TransplantUnited States
-
Società Italiana Talassemie ed EmoglobinopatieUniversity of Palermo; University of Campania "Luigi Vanvitelli"; Fondazione... and other collaboratorsCompletedHepatitis C, Chronic | Hemoglobinopathies
-
Hospices Civils de LyonCompletedHepatocellular Carcinoma | Hepatitis C | Direct Acting Antivirals